Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome

被引：9

作者：

Vita, Serena ^{[1
]}

Di Bari, Virginia ^{[1
]}

Corpolongo, Angela ^{[1
]}

Goletti, Delia ^{[1
]}

Espinosa, Joaquin ^{[2
]}

Petracca, Sebastiano ^{[3
]}

Palmieri, Fabrizio ^{[1
]}

Nicastri, Emanuele ^{[1
]}

机构：

[1] IRCCS, Natl Inst Infect Dis, Lazzaro Spallanzani, Via Portuense 292, I-00149 Rome, Italy

[2] Univ Colorado, Linda Crnic Inst Syndrome, Sch Med, Aurora, CO 80045 USA

[3] Clin Inst Casalpalocco, Intens Care Unit, I-00124 Rome, Italy

来源：

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2021年 / 103卷

关键词：

COVID-19; pneumonia; Down syndrome; Immune dysregulation; Immune activation; PHENOTYPE;

D O I：

10.1016/j.ijid.2020.11.188

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We report two cases of Corona Virus Disease-19 (COVID-19) in patients with Down Syndrome (DS) and describe the identification, diagnosis, clinical course and management of the infection. Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract and higher rate of comorbidities. All these risk factors can contribute to more severe clinical presentations of COVID-19 in this population. It is essential to raise awareness of the clinical relevance of SARS-COV-2 infection in DS patients, as well as in other most vulnerable patients, in order to improve their management and treatment and to encourage vaccinating these individuals early, once a vaccination is available. (C) 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

引用

页码：607 / 610

页数：4

共 19 条

[1] Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity [J].

Araya, Paula ;

Waugh, Katherine A. ;

Sullivan, Kelly D. ;

Nunez, Nicolas G. ;

Roselli, Emiliano ;

Smith, Keith P. ;

Granrath, Ross E. ;

Rachubinski, Angela L. ;

Estrada, Belinda Enriquez ;

Butcher, Eric T. ;

Minter, Ross ;

Tuttle, Kathryn D. ;

Bruno, Tullia C. ;

Maccioni, Mariana ;

Espinosa, Joaquin M. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (48) :24231-24241

[2] Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review [J].

Cantini, Fabrizio ;

Goletti, Delia ;

Petrone, Linda ;

Fard, Saied Najafi ;

Niccoli, Laura ;

Foti, Rosario .

DRUGS, 2020, 80 (18) :1929-1946

[3]

Cantini F, 2020, J INFECTION, V81, P318, DOI [10.1016/j.jinf.2020.04.017, 10.1016/j.jinf.2020.06.052]

[4] Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology [J].

Channappanavar, Rudragouda ;

Perlman, Stanley .

SEMINARS IN IMMUNOPATHOLOGY, 2017, 39 (05) :529-539

[5] What people with Down Syndrome can teach us about cardiopulmonary disease [J].

Colvin, Kelley L. ;

Yeager, Michael E. .

EUROPEAN RESPIRATORY REVIEW, 2017, 26 (143)

[6] Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity [J].

Diamanti, Andrea Picchianti ;

Rosado, Maria Manuela ;

Pioli, Claudio ;

Sesti, Giorgio ;

Lagana, Bruno .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)

[7] Changes in mortality and causes of death in the Swedish Down syndrome population [J].

Englund, Annika ;

Jonsson, Bjorn ;

Zander, Cecilia Soussi ;

Gustafsson, Jan ;

Anneren, Goran .

AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2013, 161A (04) :642-649

[8]

EPSTEIN CJ, 1991, AM J HUM GENET, V49, P207

[9] High positivity of anti-CCP antibodies in patients with Down syndrome [J].

Nisihara, Renato M. ;

Skare, Thelma L. ;

Silva, Marilia B. G. ;

Messias-Reason, Iara T. ;

Oliveira, Nanci P. ;

Fiedler, Patricia T. ;

Utiyama, Shirley R. R. .

CLINICAL RHEUMATOLOGY, 2007, 26 (12) :2031-2035

[10] Genetic mechanisms involved in the phenotype of down syndrome [J].

Patterson, David .

MENTAL RETARDATION AND DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS, 2007, 13 (03) :199-206

← 1 2 →